Complete Resolution of Nonalcoholic Fatty Liver Disease After Bariatric Surgery: A Systematic Review and Meta-analysis Yung Lee, Aristithes G. Doumouras, James Yu, Karanbir Brar, Laura Banfield, Scott Gmora, Mehran Anvari, Dennis Hong Clinical Gastroenterology and Hepatology Volume 17, Issue 6, Pages 1040-1060.e11 (May 2019) DOI: 10.1016/j.cgh.2018.10.017 Copyright © 2019 AGA Institute Terms and Conditions
Figure 1 Preferred Reporting Items for Systematic Reviews and Meta-Analyses diagram. Transparent reporting of systematic reviews and meta-analysis flow diagram outlining the search strategy results from initial search to included studies. Clinical Gastroenterology and Hepatology 2019 17, 1040-1060.e11DOI: (10.1016/j.cgh.2018.10.017) Copyright © 2019 AGA Institute Terms and Conditions
Figure 2 Proportion meta-analysis forest plot of biopsy-proven complete resolution of NAFLD features. (A) Steatosis, (B) inflammation/steatohepatitis, (C) ballooning degeneration, and (D) fibrosis. ES, effect size. Clinical Gastroenterology and Hepatology 2019 17, 1040-1060.e11DOI: (10.1016/j.cgh.2018.10.017) Copyright © 2019 AGA Institute Terms and Conditions
Figure 3 Random effects meta-analysis forest plot of NAS before and after surgery. IV, inverse variance; Sx, surgery. Clinical Gastroenterology and Hepatology 2019 17, 1040-1060.e11DOI: (10.1016/j.cgh.2018.10.017) Copyright © 2019 AGA Institute Terms and Conditions
Supplementary Figure 1 Proportion meta-analysis forest plot of histologic worsening of NAFLD (liver side effects) after surgery. ES, effect size. Clinical Gastroenterology and Hepatology 2019 17, 1040-1060.e11DOI: (10.1016/j.cgh.2018.10.017) Copyright © 2019 AGA Institute Terms and Conditions
Supplementary Figure 2 Subgroup analysis of biopsy-proven complete resolution of NAFLD features in patients who received RYGB. (A) Steatosis, (B) inflammation/steatohepatitis, (C) ballooning degeneration, and (D) fibrosis. ES, effect size. Clinical Gastroenterology and Hepatology 2019 17, 1040-1060.e11DOI: (10.1016/j.cgh.2018.10.017) Copyright © 2019 AGA Institute Terms and Conditions
Supplementary Figure 3 Subgroup analysis of histologic worsening of NAFLD (liver side effects) in patients who received RYGB. ES, effect size. Clinical Gastroenterology and Hepatology 2019 17, 1040-1060.e11DOI: (10.1016/j.cgh.2018.10.017) Copyright © 2019 AGA Institute Terms and Conditions
Supplementary Figure 4 Funnel plot assessing publication bias of complete resolution of steatosis (meta-analysis outcome with the most number of studies included). Clinical Gastroenterology and Hepatology 2019 17, 1040-1060.e11DOI: (10.1016/j.cgh.2018.10.017) Copyright © 2019 AGA Institute Terms and Conditions